AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12776266 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 73
Study 10367871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contrast solution (OC)
Number of subjects: 394
Study 10367871 — intervention group
Group type: COMPARATOR
Intervention: No oral contrast solution (no OC)
Number of subjects: 394
Study 8566682 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily during 6 weeks
Number of subjects: 114
Study 8566682 — intervention group
Group type: EXPERIMENTAL
Intervention: M 1 g daily during 6 weeks
Number of subjects: 114
Study 8566682 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily plus M 750 mg daily during 4 weeks
Number of subjects: 114
Study 8566682 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Number of subjects: 114
Study 8566682 — intervention group
Group type: EXPERIMENTAL
Intervention: M 750 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Number of subjects: 114
Study 2166253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/die
Number of subjects: 23
Study 2166253 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 20 mg/die
Number of subjects: 23
Study 2166253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die
Number of subjects: 23
Study 2166253 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 40 mg/die
Number of subjects: 23
Study 7428405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine (250 or 500 micrograms/day)
Number of subjects: 24
Study 7428405 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet clonidine (300 or 450 micrograms/day)
Number of subjects: 24
Study 7428405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine
Number of subjects: 24
Study 30103252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral apixaban (10 mg twice daily for the first 7 days, then 5 mg twice daily)
Number of subjects: 1168
Study 30103252 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous dalteparin (200 IU/kg for the first month, then 150 IU/kg once daily)
Number of subjects: 1168
Study 30103252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral apixaban
Number of subjects: 1168
Study 30103252 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous dalteparin
Number of subjects: 1168
Study 26919301 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA)
Number of subjects: 42
Study 26919301 — intervention group
Group type: COMPARATOR
Intervention: Social Acknowledgment Condition (Control)
Number of subjects: 42
Study 24125790 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out defaults (options visible and preselected)
Number of subjects: 45
Study 24125790 — intervention group
Group type: COMPARATOR
Intervention: Opt-in defaults (options visible but unselected)
Number of subjects: 45
Study 22739038 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diquafosol ophthalmic solution
Number of subjects: 286
Study 22739038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 286
Study 22739038 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% and 3% diquafosol ophthalmic solutions
Number of subjects: 286
Study 22739038 — intervention group
Group type: COMPARATOR
Intervention: Placebo ophthalmic solution
Number of subjects: 286
Study 20406354 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost
Number of subjects: 80
Study 20406354 — intervention group
Group type: EXPERIMENTAL
Intervention: UniCore
Number of subjects: 80
Study 20406354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond
Number of subjects: 80
Study 20406354 — intervention group
Group type: EXPERIMENTAL
Intervention: EverStick
Number of subjects: 80
Study 18331269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 25
Study 18331269 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 25
Study 15753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg) measurement <2 ng/ml
Number of subjects: 109
Study 15753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body scan (WBS)
Number of subjects: 109
Study 15753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation dose (AD)
Number of subjects: 109
Study 15753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of cancer
Number of subjects: 109
Study 15753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 109
Study 11965203 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 58511
Study 11965203 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with aspirin
Number of subjects: 58511
Study 10372612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 421
Study 10372612 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 421
Study 7560636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal grain and grass allergies (Group 1)
Number of subjects: 145
Study 7560636 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat allergy alone (Group 2)
Number of subjects: 145
Study 7560636 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergy alone (Group 3)
Number of subjects: 145
Study 7560636 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat allergy (specific IgE binding)
Number of subjects: 145
Study 1696663 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (100 micrograms)
Number of subjects: 5
Study 1696663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 5
Study 1696663 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 5
Study 7282852 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses fitted to alter myopic refractive error
Number of subjects: 0
Study 7282852 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical manner contact lenses
Number of subjects: 0
Study 31420034 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach program participants
Number of subjects: 2199
Study 27535131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) group-based enhancement to home visiting (HV/CBT)
Number of subjects: 95
Study 27535131 — intervention group
Group type: COMPARATOR
Intervention: Home visiting as usual (HV)
Number of subjects: 95
Study 26359192 — intervention group
Group type: EXPERIMENTAL
Intervention: School meals (intervention)
Number of subjects: 726
Study 26359192 — intervention group
Group type: COMPARATOR
Intervention: Packed lunch (control)
Number of subjects: 726
Study 26359192 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EPA+DHA status
Number of subjects: 726
Study 26359192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-induced increase in EPA+DHA status
Number of subjects: 726
Study 23734617 — intervention group
Group type: COMPARATOR
Intervention: YA-only cohort
Number of subjects: 30
Study 21894807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-aortic balloon pump (IABP) support during PCI
Number of subjects: 106
Study 21894807 — intervention group
Group type: COMPARATOR
Intervention: PCI without IABP insertion (Control)
Number of subjects: 106
Study 19366790 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI at or above the 85th percentile
Number of subjects: 303
Study 19366790 — intervention group
Group type: COMPARATOR
Intervention: BMI below the 85th percentile
Number of subjects: 303
Study 19366790 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 303
Study 19366790 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity self-concept and self-efficacy, diet self-efficacy
Number of subjects: 303
Study 16776752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mixture therapy (IMT) using insulin lispro mixture 50/50 before breakfast and lunch and insulin lispro mixture 25/75 before dinner
Number of subjects: 60
Study 16776752 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine therapy
Number of subjects: 60
Study 16776752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mixture therapy (IMT)
Number of subjects: 60
Study 15220781 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (INB)
Number of subjects: 52
Study 15220781 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 52
Study 11426092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.25 mg intravenously
Number of subjects: 20
Study 11426092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate administration of DTaP, hepatitis B vaccine, and PRP-T vaccine
Number of subjects: 0
Study 9431382 — intervention group
Group type: COMPARATOR
Intervention: Combination DTaP-hepatitis B vaccine-PRP-T
Number of subjects: 0
Study 9431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of CRM197-OS
Number of subjects: 0
Study 8033939 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet medication
Number of subjects: 207
Study 8033939 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned for asymptomatic reinfarcts
Number of subjects: 207
Study 2688718 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 31050315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) and maintenance temozolomide (TMZ)
Number of subjects: 0
Study 31050315 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study 25160492 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-coaching intervention (one individualised face-to-face session and five telephone coaching sessions over 3 months)
Number of subjects: 11
Study 25160492 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-coaching intervention
Number of subjects: 11
Study 24147111 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium in obstructive jaundice group
Number of subjects: 53
Study 24147111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no obstructive jaundice)
Number of subjects: 53
Study 21125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion 80 mmol/day
Number of subjects: 60
Study 21125466 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 60
Study 21125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis from literature review (including pilot study)
Number of subjects: 60
Study 18196417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic liners
Number of subjects: 40
Study 18196417 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene liners
Number of subjects: 40
Study 18196417 — intervention group
Group type: COMPARATOR
Intervention: Control (nonoperated contralateral side)
Number of subjects: 40
Study 16845899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian modelling strategy for multivariate outcomes
Number of subjects: 0
Study 16845899 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative priors for intracluster correlation coefficients
Number of subjects: 0
Study 16845899 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified existing approach for multivariate outcomes
Number of subjects: 0
Study 15053497 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment program including fines, community service, monetary restitution, written essays, anti-shoplifting videos, apology letters, and individual and/or family counseling
Number of subjects: 286
Study 15053497 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment program
Number of subjects: 286
Study 15053497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 286
Study 10925339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 22
Study 8882238 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg.70 kg‐1 bolus at induction followed by 1 mg.70 kg‐1.h‐1 continuous infusion for 48 h)
Number of subjects: 50
Study 8882238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1812099 — intervention group
Group type: EXPERIMENTAL
Intervention: Bajra
Number of subjects: 32
Study 1812099 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley
Number of subjects: 32
Study 1812099 — intervention group
Group type: COMPARATOR
Intervention: Maize
Number of subjects: 32
Study 6613138 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (45 cases)
Number of subjects: 226
Study 6613138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose irradiation of 40 to 66 Gy (59 cases)
Number of subjects: 226
Study 6613138 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP protocol (CCNU, procarbazine, vincristine, methotrexate, prednisone in 15 day cycles - 42 cases)
Number of subjects: 226
Study 6613138 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)
Number of subjects: 226
Study 30813934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 17-alpha hydroxprogesterone caproate (17P)
Number of subjects: 800
Study 30813934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 28365852 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior glenohumeral joint approach
Number of subjects: 98
Study 28365852 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior glenohumeral joint approach
Number of subjects: 98
Study 28365852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator interval approach
Number of subjects: 98
Study 28365852 — intervention group
Group type: COMPARATOR
Intervention: Residents (1st or 2nd year)
Number of subjects: 98
Study 26771622 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-incarceration (3 weeks after release)
Number of subjects: 208
Study 21822678 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual diet plus additional food supplement (SUP, n=15)
Number of subjects: 30
Study 21822678 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (CON, n=15)
Number of subjects: 30
Study 21822678 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP
Number of subjects: 30
Study 21822678 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 30
Study 19570929 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 55
Study 19570929 — intervention group
Group type: COMPARATOR
Intervention: Computer games control condition
Number of subjects: 55
Study 17686833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric, low-fat diet (n = 20)
Number of subjects: 35
Study 17686833 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance diet (n = 15)
Number of subjects: 35
Study 15339761 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d for 4 weeks, escalated to 120 mg/d for 4 weeks
Number of subjects: 109
Study 15339761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 11498677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 9849386 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium-impregnated silicone rubber spheres (2 mm in diameter)
Number of subjects: 0
Study 9849386 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA markers (3.0 mm in diameter)
Number of subjects: 0
Study 9849386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tantalum marker (2.5 mm in diameter)
Number of subjects: 0
Study 9849386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring-shaped markers in PMMA (2.6 mm and 3.0 mm in diameter)
Number of subjects: 0
Study 9138335 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and mitoxantrone
Number of subjects: 25
Study 9138335 — intervention group
Group type: COMPARATOR
Intervention: Citarabine (standard, intermediate or high doses) combined with daunomicin or mitoxantrone
Number of subjects: 25
Study 2476604 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplements (64 mmol daily)
Number of subjects: 48
Study 2476604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (made of starch with coating)
Number of subjects: 48
Study 1259099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 20
Study 1259099 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 20
Study 31300874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinsing
Number of subjects: 87
Study 31300874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth drying
Number of subjects: 87
Study 31300874 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 87
Study 29961888 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate one-time nephrological consultation after randomization, implementing KDIGO 2012 recommendations on AKI.
Number of subjects: 100
Study 29961888 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention group)
Number of subjects: 100
Study 27330154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact hydrocodone ER 45-mg tablet
Number of subjects: 0
Study 27330154 — intervention group
Group type: EXPERIMENTAL
Intervention: Finely crushed hydrocodone ER 45-mg tablet
Number of subjects: 0
Study 27330154 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone IR 45-mg powder
Number of subjects: 0
Study 27330154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24816760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA) 500 mg in 20 mL of normal saline solution, applied into the joint for 5 min at the end of surgery.
Number of subjects: 80
Study 24816760 — intervention group
Group type: COMPARATOR
Intervention: Control group received an equivalent volume of normal saline solution, applied into the joint for 5 min at the end of surgery.
Number of subjects: 80
Study 24099796 — intervention group
Group type: EXPERIMENTAL
Intervention: AJ-5 (binuclear palladacycle complex)
Number of subjects: 2
Study 21592944 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers who could see their haptic explorations of the square
Number of subjects: 40
Study 21592944 — intervention group
Group type: COMPARATOR
Intervention: Observers who could not see their haptic explorations of the square
Number of subjects: 40
Study 19736249 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric examination including diagnostics with Present State Examination and feedback regarding treatment and rehabilitation; 329 (78.3%) participated in the intervention.
Number of subjects: 420
Study 19736249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 420
Study 16893434 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg-simvastatin 20 mg
Number of subjects: 153
Study 16893434 — intervention group
Group type: COMPARATOR
Intervention: placebo-simvastatin 20 mg
Number of subjects: 153
Study 15336577 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin lispro
Number of subjects: 40
Study 15336577 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regular insulin
Number of subjects: 40
Study 10950401 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 75
Study 10950401 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 75
Study 10950401 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (amlodipine 5 mg and doxazosin 2 mg)
Number of subjects: 75
Study 10950401 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with doxazosin 4 mg
Number of subjects: 75
Study 10950401 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with amlodipine 10 mg
Number of subjects: 75
Study 9305715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus amifostine (500 mg/m2 carboplatin + 2 doses of 910 mg/m2 amifostine)
Number of subjects: 55
Study 9305715 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone (500 mg/m2)
Number of subjects: 55
Study 8422661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg daily
Number of subjects: 16
Study 8422661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg daily
Number of subjects: 16
Study 8422661 — intervention group
Group type: COMPARATOR
Intervention: Selegiline 0 mg daily (placebo)
Number of subjects: 16
Study 3537783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous edrophonium (Tensilon)
Number of subjects: 10
Study 3537783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice crackers made from ss3a/be2b mutant rice
Number of subjects: 0
Study 31690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked rice made from ss3a/be2b mutant rice
Number of subjects: 0
Study 29582447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep study-guided multidisciplinary therapy (SGMT) including overnight sleep study, continuous positive airway pressure, and behavioral therapy for OSA.
Number of subjects: 180
Study 29582447 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for acute coronary syndrome (ACS).
Number of subjects: 180
Study 27341554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis users
Number of subjects: 21
Study 27341554 — intervention group
Group type: COMPARATOR
Intervention: Intact individuals
Number of subjects: 21
Study 23880585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up at home
Number of subjects: 138
Study 23880585 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical follow-up in the outpatient clinic
Number of subjects: 138
Study 22388001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol and hydrochlorothiazide (HCTZ)
Number of subjects: 42
Study 22388001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (10 mg and 20 mg daily)
Number of subjects: 42
Study 22388001 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol posttreatment
Number of subjects: 42
Study 20478471 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic mixture (ciprofloxacin, metronidazole, minocycline)
Number of subjects: 1